Todays Report: The Polaris Venture Management Co. V L.L.C. Acquires New Position in Selecta Biosciences Inc. (SELB)

The Polaris Venture Management Co. V L.L.C. Acquires New Position in Selecta Biosciences Inc. (SELB)

Polaris Venture Management Co. V L.L.C. bought a new position in Selecta Biosciences Inc. (NASDAQ:SELB) during the second quarter, Holdings Channel reports. The institutional investor bought 1,924,151 shares of the company’s stock, valued at approximately $26,919,000. Selecta Biosciences comprises approximately 28.9% of Polaris Venture Management Co. V L.L.C.’s portfolio, making the stock its largest position.

Shares of Selecta Biosciences Inc. (NASDAQ:SELB) traded up 1.30% during midday trading on Friday, hitting $16.42. 1,845 shares of the stock were exchanged. Selecta Biosciences Inc. has a 12-month low of $10.26 and a 12-month high of $18.88. The firm has a 50-day moving average price of $13.97 and a 200-day moving average price of $13.35.

A number of brokerages recently weighed in on SELB. Zacks Investment Research raised shares of Selecta Biosciences from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research report on Tuesday, September 20th. Canaccord Genuity began coverage on shares of Selecta Biosciences in a research report on Monday, July 18th. They issued a “buy” rating and a $20.00 price target for the company. Stifel Nicolaus began coverage on shares of Selecta Biosciences in a research report on Monday, July 18th. They issued a “buy” rating and a $23.00 price target for the company. Finally, Needham & Company LLC began coverage on shares of Selecta Biosciences in a research report on Monday, July 18th. They issued a “buy” rating and a $28.00 price target for the company.

About Selecta Biosciences

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment.

Related posts

Leave a Comment